Display options
Cite
I Garcia Md L, A Mascarenhas Md M, Ahuja Md K, et al. The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation. J Atr Fibrillation. 2014;6(5):965doi: 10.4022/jafib.965.
I Garcia Md, L., A Mascarenhas Md, M., Ahuja Md, K., Aizer Md, A., Bernstein Md, N., A Bernstein Md, S., J Fowler Md, S., S Holmes Md, D., S Park Md And, D., & Chinitz Md, L. (2014). The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation. Journal of atrial fibrillation, 6(5), 965. https://doi.org/10.4022/jafib.965
I Garcia Md, Luis, et al. "The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation." Journal of atrial fibrillation vol. 6,5 (2014): 965. doi: https://doi.org/10.4022/jafib.965
I Garcia Md L, A Mascarenhas Md M, Ahuja Md K, Aizer Md A, Bernstein Md N, A Bernstein Md S, J Fowler Md S, S Holmes Md D, S Park Md And D, Chinitz Md L. The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation. J Atr Fibrillation. 2014 Feb 28;6(5):965. doi: 10.4022/jafib.965. eCollection 2014. PMID: 27957036; PMCID: PMC4956124.
Copy Download .nbib Format: NLM
Share it on

J Atr Fibrillation. 2014 Feb 28;6(5):965. doi: 10.4022/jafib.965. eCollection 2014.

The Safetyof Dabigatran Versus Warfarin in Patients Undergoing Atrial Fibrillation Ablation.

Journal of atrial fibrillation

Luis I Garcia Md, Mark A Mascarenhas Md, Kartikya Ahuja Md, Anthony Aizer Md, Neil Bernstein Md, Scott A Bernstein Md, Steve J Fowler Md, Douglas S Holmes Md, David S Park Md And, Larry Chinitz Md

Affiliations

  1. The Division of Cardiology, New York University School of Medicine, New York, United States.

PMID: 27957036 PMCID: PMC4956124 DOI: 10.4022/jafib.965

Abstract

The safety and optimal strategy of the use of dabigatran versus uninterrupted warfarin in atrial fibrillation ablation is currently unclear. We performed a retrospective analysis between July 2011-October 2012 of all patients undergoing an AF ablation who received uninterrupted warfarin therapy (199) and the routine cessation of Dabigatran therapy (126) 4 days pre-ablation. Major safety endpoints included: pericardial effusion (requiring pericardiocentesis), peripheral thromboembolism, CVA, and groin hematoma requiring blood transfusion. Minor endpoints included pericardial effusion and groin hematoma. Dabigatran was restarted the following day after ablation. The warfarin group was older, had a higher CHADS

References

  1. Circ Arrhythm Electrophysiol. 2013 Jun;6(3):460-6 - PubMed
  2. Europace. 2013 May;15(5):625-51 - PubMed
  3. Eur Heart J. 2008 Jan;29(2):155-65 - PubMed
  4. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  5. Heart. 2014 Feb;100(4):324-35 - PubMed
  6. J Cardiovasc Electrophysiol. 2013 Aug;24(8):861-5 - PubMed
  7. Heart Rhythm. 2013 Apr;10(4):483-9 - PubMed
  8. Circulation. 2008 Dec 9;118(24):2498-505 - PubMed
  9. J Cardiovasc Electrophysiol. 2011 Mar;22(3):265-70 - PubMed
  10. J Interv Card Electrophysiol. 2012 Oct;35(1):29-33 - PubMed
  11. J Am Coll Cardiol. 2012 Mar 27;59(13):1168-74 - PubMed
  12. Heart Rhythm. 2012 Apr;9(4):632-696.e21 - PubMed
  13. J Cardiovasc Electrophysiol. 2005 May;16(5):474-7 - PubMed
  14. J Interv Card Electrophysiol. 2013 Sep;37(3):233-9 - PubMed
  15. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21 - PubMed
  16. Curr Treat Options Cardiovasc Med. 2013 Aug;15(4):450-66 - PubMed
  17. J Interv Card Electrophysiol. 2013 Sep;37(3):213-21 - PubMed
  18. Pacing Clin Electrophysiol. 2013 Nov;36(11):1328-35 - PubMed

Publication Types